Soluble guanylate cyclase activator vericiguat prevents anthracycline-mediated cardiotoxicity and sarcopenia through cGMP-NLRP3-cytokine pathway: potential application in can-cer patients
Creators
-
1.
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Description
Anthracycline-induced cardiomyopathies and sarcopenia are often seen in cancer patients, affecting their quality of life and overall survival. Translational research aimed to find new cardioprotective strategies are strictly needed in cardioncology. Soluble guanylate cyclase activator vericiguat reduces heart failure rates in patients with reduced ejection fraction. In this study, we highlighted the cardioprotective and anti-inflammatory properties of vericiguat during exposure to anthracyclines and demonstrated its preventive properties of sarcopenia induced by doxorubicin, which can be exploited for potential cardioprotective strategies in cancer patients. Furthermore, vericiguat reduces chemokines and cytokines involved in cardiomyopathies through NLRP-3 pathways in human cardiomyocytes and skeletal muscle cells. The findings that emerged from this study could provide the rationale for further preclinical and clinical investigations aimed at reduce anthracycline cardiotoxicity and sarcopenia in cancer patients.
Files
Files
(40.2 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:e31305959d67f297c8da562176993990
|
40.2 kB | Download |
Additional details
Dates
- Created
-
2024-02-01Manuscript